The aortic clinical trials team is interested in seeing how exciting new aortic devices and drugs can help to improve the outcomes and quality of life for those living with aortic diseases.
Feel free to call or e-mail the Knight Cardiovascular Institute research team at 503-418-1964 or by emailing email@example.com. You will then be forwarded to the appropriate research team member who will be able to see if you qualify for any of the clinical trials being offered at OHSU.
You can also find all the of heart failure clinical trials, that are currently enrolling patients, below.
CIRT study is evaluating whether anti-inflammatory therapy with low dose of methotrexate (study drug) will reduce the occurrence of myocardial infarction, stroke, and cardiovascular death in patients with a prior history of heart attack or past evidence of major blockages in more than one artery as found on a heart catheterization and with type 2 diabetes and/or metabolic syndrome. Participants will be randomized to either methotrexate at low doses (target maximal dose 20 mg/week) or placebo. All participants will receive 1 mg folate 6 days/week and will be followed for a period of 4 years.